This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2004-2006.
Company Filing History:
Years Active: 2004-2006
Title: Innovations in Pharmaceutical Purity: The Contributions of Dusan Milivojevic
Introduction
Dusan Milivojevic is a notable inventor based in Ljubljana, Slovenia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of processes for obtaining high-purity HMG-CoA reductase inhibitors. With a total of 3 patents to his name, Milivojevic's work is crucial for the advancement of antihypercholesterolemic agents.
Latest Patents
Milivojevic's latest patents focus on the process for obtaining HMG-CoA reductase inhibitors such as Lovastatin, Pravastatin, Simvastatin, Mevastatin, and Atorvastatin. These compounds are essential in managing high plasma cholesterol levels. His innovative approach involves using displacement chromatography to isolate these inhibitors, ensuring high purity and yield while maintaining ecological balance. The process includes clarifying mycelium broth, acidifying the concentrate, and extracting the inhibitors with ethyl acetate, followed by crystallization steps that enhance the purity of the final product.
Career Highlights
Dusan Milivojevic is currently associated with Lek Pharmaceuticals D.d., a leading pharmaceutical company. His work has not only contributed to the company's portfolio but has also set new standards in the industry for the production of safe and effective pharmaceuticals. His focus on purity and efficiency in pharmaceutical processes is a testament to his commitment to improving healthcare outcomes.
Collaborations
Milivojevic has collaborated with notable colleagues such as Rok Grahek and Andrej Bastarda. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas, further enhancing the quality of their research and development efforts.
Conclusion
Dusan Milivojevic's contributions to the field of pharmaceuticals, particularly in the area of HMG-CoA reductase inhibitors, highlight the importance of innovation in healthcare. His work not only improves the efficacy of treatments but also ensures patient safety through high-purity products.